Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

378 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmaceutical cost savings from the treatment of oncology patients in clinical trials.
Gómez Mediavilla B, Lanza León P, Martínez Callejo V, Cantarero Prieto D, Lanza Postigo M, Salcedo Lambea M, Blanco Mesonero Y, Ochagavia Sufrategui M, Durán I, Sarabia Cobo CM. Gómez Mediavilla B, et al. Among authors: duran i. Biomed J. 2024 Apr 26:100742. doi: 10.1016/j.bj.2024.100742. Online ahead of print. Biomed J. 2024. PMID: 38679197 Free article.
RENO Study: Clinical characteristics, treatment patterns and survival results in patients with metastatic renal cell carcinoma in Northern Spain.
Badiola LB, Milagro NL, Lavín DC, Peraita SL, Ibarbia MA, Kareaga MM, Fernández Del Rivero TP, Otero DSP, López VA, Fernández CÁ, Emborujo AL, Arnaiz IG, Rodríguez RF, Sagastibeltza N, Duran I; GONORTE Collaborative Group. Badiola LB, et al. Among authors: duran i. Semin Oncol. 2024 Mar 4:S0093-7754(24)00005-8. doi: 10.1053/j.seminoncol.2024.02.002. Online ahead of print. Semin Oncol. 2024. PMID: 38604897 Free article.
Measurement of the ^{140}Ce(n,γ) Cross Section at n_TOF and Its Astrophysical Implications for the Chemical Evolution of the Universe.
Amaducci S, Colonna N, Cosentino L, Cristallo S, Finocchiaro P, Krtička M, Massimi C, Mastromarco M, Mazzone A, Maugeri EA, Mengoni A, Roederer IU, Straniero O, Valenta S, Vescovi D, Aberle O, Alcayne V, Andrzejewski J, Audouin L, Babiano-Suarez V, Bacak M, Barbagallo M, Bennett S, Berthoumieux E, Billowes J, Bosnar D, Brown A, Busso M, Caamaño M, Caballero-Ontanaya L, Calviño F, Calviani M, Cano-Ott D, Casanovas A, Cerutti F, Chiaveri E, Cortés G, Cortés-Giraldo MA, Damone LA, Davies PJ, Diakaki M, Dietz M, Domingo-Pardo C, Dressler R, Ducasse Q, Dupont E, Durán I, Eleme Z, Fernández-Domínguez B, Ferrari A, Furman V, Göbel K, Garg R, Gawlik-Ramięga A, Gilardoni S, Gonçalves IF, González-Romero E, Guerrero C, Gunsing F, Harada H, Heinitz S, Heyse J, Jenkins DG, Junghans A, Käppeler F, Kadi Y, Kimura A, Knapová I, Kokkoris M, Kopatch Y, Kurtulgil D, Ladarescu I, Lederer-Woods C, Leeb H, Lerendegui-Marco J, Lonsdale SJ, Macina D, Manna A, Martínez T, Masi A, Mastinu P, Mendoza E, Michalopoulou V, Milazzo PM, Mingrone F, Moreno-Soto J, Musumarra A, Negret A, Nolte R, Ogállar F, Oprea A, Patronis N, Pavlik A, Perkowski J, Petrone C, Piersanti L, Pirovano E, Porras I, Praena J, … See abstract for full author list ➔ Amaducci S, et al. Among authors: duran i. Phys Rev Lett. 2024 Mar 22;132(12):122701. doi: 10.1103/PhysRevLett.132.122701. Phys Rev Lett. 2024. PMID: 38579210
A perspective on muscle phenotyping in musculoskeletal research.
Foessl I, Ackert-Bicknell CL, Kague E, Laskou F, Jakob F, Karasik D, Obermayer-Pietsch B; Co-authors; Alonso N, Bjørnerem Å, Brandi ML, Busse B, Calado Â, Cebi AH, Christou M, Curran KM, Hald JD, Semeraro MD, Douni E, Duncan EL, Duran I, Formosa MM, Gabet Y, Ghatan S, Gkitakou A, Hassler EM, Högler W, Heino TJ, Hendrickx G, Khashayar P, Kiel DP, Koromani F, Langdahl B, Lopes P, Mäkitie O, Maurizi A, Medina-Gomez C, Ntzani E, Ohlsson C, Prijatelj V, Rabionet R, Reppe S, Rivadeneira F, Roshchupkin G, Sharma N, Søe K, Styrkarsdottir U, Szulc P, Teti A, Tobias J, Valjevac A, van de Peppel J, van der Eerden B, van Rietbergen B, Zekic T, Zillikens MC. Foessl I, et al. Among authors: duran i. Trends Endocrinol Metab. 2024 Mar 28:S1043-2760(24)00018-3. doi: 10.1016/j.tem.2024.01.004. Online ahead of print. Trends Endocrinol Metab. 2024. PMID: 38553405 Free article. Review.
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, Gümüş M, Mar N, Loriot Y, Fléchon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, van der Heijden MS; EV-302 Trial Investigators. Powles T, et al. Among authors: duran i. N Engl J Med. 2024 Mar 7;390(10):875-888. doi: 10.1056/NEJMoa2312117. N Engl J Med. 2024. PMID: 38446675 Clinical Trial.
378 results